Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Novo Nordisk is the lead sponsor of 94 current clinical trials in our USA, UK, India, China, Ireland and EU (CTIS) registers. 36 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Semaglutide, Cagrilintide and NNC0487-0111. The most-studied condition is Obesity.

Company profile on this site (news, sites, medicines, approvals): Novo Nordisk A/S (DK) →

ClinicalTrials.gov trials by status

Recruiting3643%
Not yet open78%
Active, closed2733%
By invitation1316%

Trials by phase

Phase 34251%
Phase 11518%
Observational1417%
Phase 21012%
Phase 422%

Clinical trials sponsored by Novo Nordisk

83 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain NCT07509307 · Obesity, Overweight, Osteoarthritis, Knee Drug: NNC0487-0111	Phase 3	Recruiting	2026-04	USA
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis NCT07207811 · ClinicalTrials.gov ↗ · Transthyretin Amyloid Cardiomyopathy (ATTR CM) Drug: NNC6019-0001	Phase 3	Recruiting	2025-10	Ireland, UK, USA, China
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea NCT07571005 · ClinicalTrials.gov ↗ · Obesity, Overweight, Obstructive Sleep Apnoea Drug: NNC0487-0111	Phase 3	Recruiting	2026-05	USA, India, China
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea NCT07571109 · ClinicalTrials.gov ↗ · Obesity, Overweight, Obstructive Sleep Apnoea Drug: NNC0487-0111	Phase 3	Recruiting	2026-05	USA, India, China
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity NCT07567001 · ClinicalTrials.gov ↗ · Obesity, Heart Failure Drug: NNC0487-0111	Phase 3	Recruiting	2026-05	UK, USA, India, China
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese NCT07411560 · Overweight, Obese Drug: Cagrilintide	Phase 1	Recruiting	2026-02	UK
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy NCT06979375 · ClinicalTrials.gov ↗ · Heart Failure Drug: CDR132L	Phase 2	Recruiting	2025-06	UK, India
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia NCT06609226 · ClinicalTrials.gov ↗ · Sickle Cell Disease, Thalassemia	Phase 3	Recruiting	2025-01	UK, USA, India
A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure NCT07218627 · Heart Failure	Phase 1	Recruiting	2025-10	UK
A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India NCT07157423 · ClinicalTrials.gov ↗ · Severe Postpartum Haemorrhage	Phase 4	Recruiting	2025-08	India
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity NCT07767175 · Overweight, Obesity Drug: Semaglutide	Phase 1	Recruiting	2026-08	USA
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease NCT06612268 · ClinicalTrials.gov ↗ · Sickle Cell Disease Drug: Etavopivat	Phase 3	Recruiting	2025-02	UK, USA, India
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease NCT06717698 · ClinicalTrials.gov ↗ · Chronic Kidney Disease Drug: Semaglutide	Phase 2	Recruiting	2024-12	USA, India
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight NCT07770841 · Overweight, Obesity Drug: Semaglutide	Phase 3	Recruiting	2026-08	USA
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy NCT06979362 · ClinicalTrials.gov ↗ · Heart Failure Drug: CDR132L	Phase 2	Recruiting	2025-06	UK, USA, India
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight NCT07253285 · ClinicalTrials.gov ↗ · Overweight, Obesity Drugs: Cagrilintide, Semaglutide	Phase 3	Recruiting	2026-01	UK, USA, India, China
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications NCT07797335 · ClinicalTrials.gov ↗ · Type 2 Diabetes, Cardiovascular Risk Drug: Zenagamtide	Phase 3	Recruiting	2026-08	UK, USA, India, China
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A NCT07220564 · ClinicalTrials.gov ↗ · Haemophilia A	Phase 1	Recruiting	2025-10	UK, USA
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes NCT07282613 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2 Drug: CagriSema	Phase 3	Recruiting	2026-08	USA, India
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes NCT07668388 · Diabetes Mellitus, Type 2 Drugs: Semaglutide, UBT251	Phase 2	Recruiting	2026-06	USA
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight NCT07339423 · ClinicalTrials.gov ↗ · Obesity Drug: NNC0487-0111	Phase 3	Recruiting	2026-02	UK, USA
Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases NCT06891365 · ClinicalTrials.gov ↗ · Healthy Volunteers, Hepatic Steatosis	Phase 1	Recruiting	2025-03	UK
Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians NCT07682363 · ClinicalTrials.gov ↗ · Liver Disease	Observational	Recruiting	2026-06	China
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes NCT07415954 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2 Drugs: NNC0662-0419, Semaglutide	Phase 2	Recruiting	2026-04	USA
A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight NCT07525791 · ClinicalTrials.gov ↗ · Overweight, Obesity Drugs: Acetaminophen, NNC0662-0419	Phase 1	Recruiting	2026-04	USA
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity NCT07395687 · ClinicalTrials.gov ↗ · Overweight, Obesity Drug: UBT251	Phase 2	Recruiting	2026-02	USA
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight NCT07564414 · ClinicalTrials.gov ↗ · Obesity, Type 2 Diabetes Drugs: CagriSema, Semaglutide	Phase 3	Recruiting	2026-05	USA
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight NCT07710768 · ClinicalTrials.gov ↗ · Obesity, Overweight Drug: UBT251	Phase 1	Recruiting	2026-07	USA
A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity NCT07437079 · ClinicalTrials.gov ↗ · Overweight, Obesity	Phase 1	Recruiting	2026-02	USA
A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity NCT07566390 · ClinicalTrials.gov ↗ · Obesity, Overweight	Phase 1	Recruiting	2026-05	USA
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight NCT07533175 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Overweight, Obesity Drug: NNC0487-0111	Phase 3	Recruiting	2026-04	USA
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain NCT07481630 · ClinicalTrials.gov ↗ · Obesity, Knee Osteoarthritis (OA) Drug: NNC0487-0111	Phase 3	Recruiting	2026-04	USA
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events NCT07607587 · ClinicalTrials.gov ↗ · Obesity, Overweight Drug: Cagrilintide	Phase 1	Recruiting	2026-05	USA
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight NCT07745504 · ClinicalTrials.gov ↗ · Overweight, Obesity Drug: Cagrilintide	Phase 3	Recruiting	2026-08	USA
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) NCT07225816 · ClinicalTrials.gov ↗ · Obesity Drugs: Liraglutide, Semaglutide	Phase 1	Recruiting	2025-11	USA
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia NCT06859073 · ClinicalTrials.gov ↗ · Healthy Volunteers, Hyperuricemia	Phase 1	Recruiting	2024-11	USA
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight NCT07400107 · Obesity, Overweight, Diabetes Mellitus, Type 2 Drugs: NNC0487-0111, Semaglutide	Phase 3	Not yet open	2026-05	USA, India
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A NCT07830732 · ClinicalTrials.gov ↗ · Haemophilia A	Phase 3	Not yet open	2026-10	UK, USA, India
AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight NCT07668401 · ClinicalTrials.gov ↗ · Obesity, Overweight Drug: Zenagamtide	Phase 3	Not yet open	2027-01	India
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema NCT07817251 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2 Drug: CagriSema	Phase 3	Not yet open	2026-09	USA
A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People NCT07829406 · ClinicalTrials.gov ↗ · Healthy Volunteers	Phase 1	Not yet open	2026-09	USA
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight NCT07720271 · ClinicalTrials.gov ↗ · Overweight, Obesity Drug: Zenagamtide	Phase 3	Not yet open	2026-09	USA
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide NCT07668414 · ClinicalTrials.gov ↗ · Overweight, Obesity Drugs: Semaglutide, Zenagamtide	Phase 3	Not yet open	2026-09	USA
Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia NCT07163260 · Haemophilia	Observational	By invitation	2025-01	India
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters NCT06709040 · Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2 Drug: Somapacitan	Observational	By invitation	2024-12	UK
A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information NCT05718570 · Adult Growth Hormone Deficiency Drug: Somapacitan	Observational	By invitation	2023-02	USA
An Observational Study of Patients With Moderate Parkinson's Disease NCT05779475 · Parkinson Disease	Observational	By invitation	2023-04	UK, USA
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice NCT07055607 · ClinicalTrials.gov ↗ · Obesity Drug: Semaglutide	Observational	By invitation	2025-05	UK
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy NCT05872022 · ClinicalTrials.gov ↗ · Pregnancy, Obesity, Overweight	Observational	By invitation	2023-07	UK, USA
A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN NCT03745924 · ClinicalTrials.gov ↗ · Haemophilia B Drug: Nonacog beta pegol	Observational	By invitation	2019-04	UK
Adverse Event Data Collection From External Registries on Nonacog Beta Pegol NCT03690336 · ClinicalTrials.gov ↗ · Haemophilia B Drug: Nonacog beta pegol	Observational	By invitation	2018-10	UK
Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma NCT07713901 · ClinicalTrials.gov ↗ · Medullary Thyroid Carcinoma	Observational	By invitation	2025-12	USA
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) NCT01511393 · ClinicalTrials.gov ↗ · Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma	Observational	By invitation	2012-01	USA
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy NCT05503927 · ClinicalTrials.gov ↗ · Pregnancy, Obesity, Overweight	Observational	By invitation	2020-02	USA
Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec NCT07658417 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2 Drug: Insulin icodec	Observational	By invitation	2026-07	China
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China NCT07456774 · ClinicalTrials.gov ↗ · Type 2 Diabetes	Observational	By invitation	2026-02	China
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors NCT05135559 · Haemophilia A and B With and Without Inhibitors Drug: Concizumab	Phase 3	Active, closed	2022-03	UK, USA, India
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack NCT06118281 · Cardiovascular Risk, Acute Myocardial Infarction (AMI) Drug: Ziltivekimab	Phase 3	Active, closed	2024-06	UK, USA, India, China
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight NCT05567796 · Obesity Drugs: Cagrilintide, Semaglutide	Phase 3	Active, closed	2022-11	UK, USA, India, China
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) NCT04822181 · Non-alcoholic Steatohepatitis Drug: Semaglutide	Phase 3	Active, closed	2021-04	Ireland, UK, USA, India, China
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels NCT05669755 · Cardiovascular Disease Drugs: Cagrilintide, Semaglutide	Phase 3	Active, closed	2023-03	Ireland, UK, USA, India
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term NCT07011667 · Obesity Drug: CagriSema	Phase 3	Active, closed	2025-06	USA
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow NCT05330325 · SGA, Turner Syndrome, Noonan Syndrome, ISS Drugs: Norditropin, Somapacitan	Phase 3	Active, closed	2022-08	Ireland, UK, USA, India, China
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A NCT05685238 · ClinicalTrials.gov ↗ · Haemophilia A, Haemophilia A With Inhibitors	Phase 3	Active, closed	2023-02	Ireland, UK, USA, India, China
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation NCT06200207 · ClinicalTrials.gov ↗ · Heart Failure, Systemic Inflammation Drug: Ziltivekimab	Phase 3	Active, closed	2024-04	UK, USA, India
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day NCT03878446 · ClinicalTrials.gov ↗ · Short Stature Children Born Small for Gestational Age (SGA) Drugs: Norditropin, Somapacitan	Phase 2	Active, closed	2019-07	Ireland, UK, USA, India
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes NCT03811561 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2 Drug: Semaglutide	Phase 3	Active, closed	2019-05	UK, USA, India
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors NCT04082429 · ClinicalTrials.gov ↗ · Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors Drug: Concizumab	Phase 3	Active, closed	2019-11	UK, USA, India
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss NCT06571383 · ClinicalTrials.gov ↗ · Obesity Drug: Semaglutide	Phase 4	Active, closed	2024-09	UK, USA
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity NCT04775082 · ClinicalTrials.gov ↗ · Obesity Drug: Liraglutide	Phase 3	Active, closed	2021-03	USA, India
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors NCT04083781 · ClinicalTrials.gov ↗ · Haemophilia A With Inhibitors, Haemophilia B With Inhibitors Drug: Concizumab	Phase 3	Active, closed	2019-10	UK, USA, India
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide NCT07220759 · ClinicalTrials.gov ↗ · Overweight, Obesity, Type 2 Diabetes Drug: Cagrilintide	Phase 3	Active, closed	2025-11	UK, USA
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide NCT07220642 · ClinicalTrials.gov ↗ · Obesity, Overweight Drug: Cagrilintide	Phase 3	Active, closed	2025-11	UK, USA
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity NCT06780449 · ClinicalTrials.gov ↗ · Obesity Drugs: Cagrilintide, Semaglutide	Phase 3	Active, closed	2025-02	UK, USA
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight NCT05726227 · ClinicalTrials.gov ↗ · Obesity Drug: Semaglutide	Phase 3	Active, closed	2023-07	UK, USA
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss NCT07503210 · ClinicalTrials.gov ↗ · Obesity Drug: NNC0487-0111	Phase 3	Active, closed	2026-04	UK, USA
A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity NCT06577766 · ClinicalTrials.gov ↗ · Obesity, Overweight	Phase 1	Active, closed	2024-09	USA
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes NCT07076199 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 1 Drugs: Insulin aspart, Insulin glargine, Insulin icodec	Phase 3	Active, closed	2025-08	USA
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet NCT07184086 · ClinicalTrials.gov ↗ · Obesity	Phase 1	Active, closed	2025-09	USA
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity NCT07184632 · ClinicalTrials.gov ↗ · Overweight, Obesity Drug: NNC0662-0419	Phase 2	Active, closed	2025-10	USA
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity NCT07639021 · ClinicalTrials.gov ↗ · Obesity Drugs: NNC0662-0419, Semaglutide	Phase 2	Active, closed	2026-06	USA
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 NCT05723835 · ClinicalTrials.gov ↗ · SGA, Turner Syndrome, Noonan Syndrome	Phase 3	Active, closed	2023-02	USA
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis NCT06260709 · ClinicalTrials.gov ↗ · Transthyretin Amyloid Cardiomyopathy (ATTR CM) Drug: NNC6019-0001	Phase 2	Active, closed	2024-02	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Novo Nordisk in the EU trials register (CTIS)

11 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Novo Nordisk as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A global phase 3 randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in children with sickle cell disease 2025-524464-38-00 · Hemic and Lymphatic Diseases	Phase 3	Authorised	France, Netherlands
Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE) 2026-525182-53-00 · Cardiovascular Diseases	Phase 3	Authorised	Denmark, Czechia, Greece + 6 more
A study assessing the safety, tolerability, pharmacokinetics and efficacy of single and multiple doses of NNC0638-0355 in participants with overweight or obesity 2026-526797-16-00 · Nutritional and Metabolic Diseases	Phase 1	Authorised	Netherlands
A research study looking into how a high dose of s.c. semaglutide works with emptying of the stomach in people with excess body weight 2026-526083-20-00 · Nutritional and Metabolic Diseases	Phase 1	Authorised	Austria
A research study looking at the effect of timing of meal after dosing and water volume at dosing on how the medicine zenagamtide is taken up by the body of participants with overweight or obesity 2025-521383-35-00 · Not possible to specify	Phase 1	Authorised	Germany
Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8) 2024-520446-31-00 · CTIS ↗ · Nutritional and Metabolic Diseases Drug: Semaglutide	Phase 3	Ongoing	Germany, Croatia, Portugal + 4 more
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2) 2024-520441-23-00 · CTIS ↗ · Nutritional and Metabolic Diseases	Phase 3	Ongoing	Italy, Croatia, Hungary + 2 more
Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity 2023-509176-42-00 · CTIS ↗ · Nutritional and Metabolic Diseases Drugs: Cagrilintide, Semaglutide	Phase 3	Ongoing	Slovakia, Austria, Spain + 11 more
Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study 2025-523260-20-00 · CTIS ↗ · Hormonal diseases Drug: Semaglutide	Phase 2	Ongoing	Spain, Hungary, Portugal + 3 more
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease 2024-519881-32-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 1	Authorised	France
EFFectiveness of once-weekly insulin ICodec versus once-daily basal Insulin analogues in an insulin-naïve type 2 diabEtes population in real-world cliNical pracTice- The EFFICIENT pragmatic study 2024-520068-32-00 · CTIS ↗ · Nutritional and Metabolic Diseases Drugs: Insulin glargine, Insulin icodec	Phase 4	Authorised	Germany, Italy

Drugs in Novo Nordisk trials

20 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Novo Nordisk trials

48 conditions

Obesity39 Overweight25 Diabetes Mellitus, Type 28 Heart Failure5 Type 2 Diabetes4Haemophilia A3Healthy Volunteers3Haemophilia A With Inhibitors2Transthyretin Amyloid Cardiomyopathy (ATTR CM)2Cardiovascular Risk2Pregnancy2 Sickle Cell Disease2Haemophilia B2Medullary Thyroid Carcinoma2Obstructive Sleep Apnoea2Non-alcoholic Steatohepatitis1Cardiovascular Disease1SGA, Turner Syndrome, Noonan Syndrome, ISS1Short Stature Children Born Small for Gestational Age (SGA)1Haemophilia A and B With and Without Inhibitors1Acute Myocardial Infarction (AMI)1Growth Hormone Deficiency1Neoplasms1 Diabetes Mellitus Type 21

By trial register

Register	Trials	Recruiting
Clinical trials in USA	69	30
Clinical trials in UK	38	13
Clinical trials in India	29	12
Clinical trials in China	14	7
Clinical trials in Ireland	6	1
EU register (CTIS)	11	—

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Obesity

Sponsor	Trials
Eli Lilly and Company	39
Amgen	7
China-Japan Friendship Hospital	6
Kailera	5
Innovent Biologics (Suzhou)	5
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	4
Hangzhou Sciwind Biosciences	4
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	3
Peking University Third Hospital	3
Chinese Academy of Sciences	3

Sponsors with the most current trials registered for this condition.

Questions about Novo Nordisk trials

How many clinical trials does Novo Nordisk sponsor?

Novo Nordisk is the lead sponsor of 83 current trials on ClinicalTrials.gov in our USA, UK, India, China and Ireland registers, and 11 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Novo Nordisk trials recruiting?

Yes. 36 of its 83 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Novo Nordisk testing?

Its current trials name 20 drugs and biologicals as interventions. The most frequent are Semaglutide (22), Cagrilintide (10), NNC0487-0111 (9), CagriSema (4) and NNC0662-0419 (4). The number in brackets is how many of its trials name each drug.

Does Novo Nordisk have clinical trials in Ireland?

Yes. 6 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Novo Nordisk clinical trials